Most Ocular Trial Delays Are Operational, Not Scientific. A 30-Minute Review Can Tell You Where You Stand.
One team. Single-call accountability for ophthalmic trial execution from protocol consultation through nationwide field deployment.
When ocular endpoints are overlooked during protocol development, it can cause:
🚫 IRB pushback 🚫 Referral bottlenecks 🚫 Missed enrollment milestones 🚫 Amendments that cost weeks and thousands
Our team has reviewed protocols across 45+ ocular trials. We know exactly where the operational gaps hide.
No obligation. No preparation required.
"While working with 20/20 Onsite for previous and current studies, we have been able to provide ophthalmological services that were previously not feasible for our clinical units. Doing so has been very successful in providing safety and ophthalmological oversight of study participants – as required by good clinical practices and the sponsor protocol."
- Dr. David Wyatt, Vice-President and Global Medical Lead, Syneos Health
What You’ll Get in This Review
Our ophthalmic clinical experts will help with:
Audit your current protocol language around ocular endpoints
Red flags we’ve seen lead to real-world delays
Suggest operational improvements to reduce patient burden
Recommend integration options that fit your timeline and site structure
Show how to reduce dropout (from 30% to as low as 9%) and meet enrollment targets faster
